NCCN Guidelines Insights: T-cell lymphomas, version 1.2021 Guidelines

  


Authors: Horwitz, S. M.; Ansell, S.; Ai, W. Z.; Barnes, J.; Barta, S. K.; Clemens, M. W.; Dogan, A.; Goodman, A. M.; Goyal, G.; Guitart, J.; Halwani, A.; Haverkos, B. M.; Hoppe, R. T.; Jacobsen, E.; Jagadeesh, D.; Jones, A.; Kim, Y. H.; Mehta-Shah, N.; Olsen, E. A.; Pro, B.; Rajguru, S. A.; Rozati, S.; Said, J.; Shaver, A.; Shustov, A.; Sokol, L.; Torka, P.; Torres-Cabala, C.; Wilcox, R.; William, B. M.; Zain, J.; Dwyer, M. A.; Sundar, H.
Title: NCCN Guidelines Insights: T-cell lymphomas, version 1.2021
Abstract: Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 18
Issue: 11
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2020-11-01
Start Page: 1460
End Page: 1467
Language: English
DOI: 10.6004/jnccn.2020.0053
PUBMED: 33152703
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095784379&doi=10.6004%2fjnccn.2020.0053&partnerID=40&md5=e8753a6f013b1767849d484c155b09f2
Notes: Article -- Export Date: 1 December 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Steven M Horwitz
    645 Horwitz
  2. Ahmet Dogan
    454 Dogan
Related MSK Work